Komori
Otsuka Holdings (4578) · TargetAdvanced

Average annual business profit growth of 10% or more

First written in FY2019. 7 of 15 entries say "Advanced", first in FY2020. Latest entry: FY2026-H1.

15entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019OtherFY2021-Q3 – FY2022-Q3AdvancedFY2022 – FY20232020: 120202021: 220212022: 320222023: 420232024: 120242025: 220252026: 22026
Same theme, other companies
Setting and achieving performance targets under the medium-term management planA theme 791 companies write about · 75 as a headwind · 1062 as a tailwind

The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 133 companies compared. The sentences above are computed from all 133.Comparing 200 of the theme's 1182 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AdvancedAnnual report

    「Supported by steady sales growth, business profit was ¥280,579 million, up 17.3% year on year, and operating profit was ¥278,544 million, up 15.0%.」

    In relation to the growth stage of business profit growth of at least double digits set out in the Fourth Medium-Term Management Plan, business profit for the interim consolidated accounting period increased 17.3% year on year.
  2. FY2025Slowing business profit growthAnnual report

    「Supported by steady sales growth, business profit increased to ¥446,129 million, up 3.6%.」

    Against the growth stage of business profit growth of at least double digits set out in the Fourth Medium-Term Management Plan, the business profit growth rate for fiscal 2025 was 3.6%.
  3. FY2025-H1AdvancedAnnual report

    「Supported by steady sales growth, business profit increased to ¥239,221 million, up 12.0% year on year.」

    During the interim consolidated accounting period under the Fourth Medium-Term Management Plan, business profit increased 12.0% year on year, representing double-digit growth.
  4. FY2024ReframedAnnual report

    「Keeping the adjustment phase caused by LOE* short, return to a growth stage with double-digit business profit growth」

    After achieving the Third Medium-Term Management Plan target of an average annual growth rate of at least 10%, the Fourth Medium-Term Management Plan has reframed its objective as shortening the adjustment caused by the end of the exclusive sales period and returning to a business profit growth rate in the double digits.
  5. FY2023AchievedAnnual report

    「The company achieved a high growth rate of just over 20% per year, substantially exceeding the Third Medium-Term Management Plan performance target of business profit growth at an average annual rate of at least 10%.」

    The company stated that, in the final year of the Third Medium-Term Management Plan covering fiscal 2019 through fiscal 2023, it exceeded the target of an average annual business profit growth rate of at least 10%, achieving just over 20% per year.
  6. FY2023-Q3AdvancedAnnual report

    「As a result of higher-than-expected sales growth and appropriate control of selling, general and administrative expenses, business profit increased substantially to ¥258,483 million, up 105.6% year on year.」

    In relation to the Third Medium-Term Management Plan target of an average annual business profit growth rate of at least 10%, cumulative business profit for the third quarter increased 105.6% from the same quarter of the previous year.
  7. FY2023-Q2AdvancedAnnual report

    「As a result of higher-than-expected sales growth and appropriate control of selling, general and administrative expenses, business profit increased substantially to ¥155,047 million, up 98.5% year on year.」

    In relation to the Third Medium-Term Management Plan target of an average annual business profit growth rate of at least 10%, cumulative business profit for the second quarter increased 98.5% year on year.
  8. FY2023-Q1AdvancedAnnual report

    「As a result of higher-than-expected sales growth and appropriate control of selling, general and administrative expenses, business profit increased substantially to ¥73,681 million, up 73.5% year on year.」

    Regarding the metric related to the Third Medium-Term Management Plan's business profit growth target, business profit for the first quarter increased 73.5% from the same quarter of the previous year.
  9. FY2022AdvancedAnnual report

    「As a result of higher-than-expected sales growth and appropriate control of selling, general and administrative expenses, business profit was ¥174,917 million, up 11.3% year on year. In fiscal 2023, the company will continue to pursue the Third Medium-Term Management Plan performance target of business profit growth at an average annual rate of at least 10%.」

    Business profit increased 11.3% year on year in fiscal 2022, indicating progress toward the target of business profit growth at an average annual rate of at least 10%.
  10. FY2022-Q3Third-quarter business profit decline continuesAnnual report

    「As a result of these aggressive investments in research and development, business profit was ¥125,694 million, down 19.4% year on year.」

    Regarding the metric related to the target of an average annual business profit growth rate of at least 10%, cumulative business profit for the third quarter was down 19.4% from the same quarter of the previous year. The text does not assess progress toward the target.
  11. FY2022-Q2Second-quarter business profit declineAnnual report

    「Business profit was ¥78,126 million, down 25.1% year on year.」

    Regarding the metric related to the Third Medium-Term Management Plan target of an average annual business profit growth rate of at least 10%, cumulative business profit for the second quarter was down 25.1% year on year. The text does not assess progress toward the target.
  12. FY2021RestatedAnnual report

    「The four global products have grown significantly beyond plan, and from fiscal 2022 onward the company will continue to pursue the Third Medium-Term Management Plan performance target of business profit growth at a compound annual growth rate of 10% or more.」

    The target of an average annual growth rate of at least 10% in business profit remains in place. Business profit for fiscal 2021 was 98.2% of plan and down 27.6% year on year, but the company stated that it would continue to pursue the target from fiscal 2022 onward.
  13. FY2021-Q3Third-quarter decline in business profitAnnual report

    「Business profit was ¥155,863 million, down 17.4%.」

    With respect to the indicator related to the Third Medium-Term Management Plan target of business profit growth at a compound annual growth rate of 10% or more, business profit for the nine months ended the third quarter on a consolidated basis declined 17.4% year on year. The text does not state an assessment of progress toward the target.
  14. FY2020AdvancedAnnual report

    「Business profit grew steadily, increasing 15.9% year on year, due to higher revenue from four global products and greater cost efficiency. Progress is also steady toward the Third Medium-Term Management Plan performance target of business profit growth at a compound annual growth rate of 10% or more.」

    Against the target of business profit growth at a compound annual growth rate of 10% or more, business profit in the second year increased 15.9% year on year, indicating steady progress.
  15. FY2019First statedAnnual report

    「<Performance target> Business profit growth at a compound annual growth rate of 10% or more」

    As a performance target under the Third Medium-Term Management Plan, the company has set a business profit compound annual growth rate of 10% or more over the five-year period from fiscal 2019 through fiscal 2023. The target is to be achieved through organic growth of core products and brands and proactive R&D investment.
Moved together

"Pipeline Progress in Clinical Development, Regulatory Approval and Commercialization" moved the same way as this thread, in the same document, in 8 of its 15 moves.

888777★123456
  1. ★This thread
  2. 1Pipeline Progress in Clinical Development, Regulatory Approval and Commercialization8×
  3. 2Expansion of Overseas Sales of Pharmaceutical and Health-Related Products8×
  4. 3Improving the Earnings Structure of the Consumer-Related Business8×
  5. 4Sustainable growth driven by 3 global products and 3 next-generation products7×
  6. 5Continued investment in research and development7×
  7. 6Investment Plan for Research and Production Facilities7×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Otsuka Holdings's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Average annual business profit growth of 10% or more | Otsuka Holdings Co.,Ltd. (4578) | Komori